Document Detail

Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei.
MedLine Citation:
PMID:  15801987     Owner:  NLM     Status:  MEDLINE    
The pharmacological efficacy of serotonergic-acting drugs suggest that patients with obsessive-compulsive disorder (OCD) may have alterations in their cerebral serotonergic (5-HT) receptor system, and previous neuroimaging studies of OCD patients have shown abnormalities in several fronto-subcortical regions. In this study we investigated cerebral 5-HT(2A) receptor binding in 15 untreated OCD patients and in 15 age- and gender-matched healthy volunteers by magnetic resonance imaging and [(18)F]altanserin positron emission tomography (PET). Eleven of the patients were rescanned with PET after receiving treatment with a selective serotonin reuptake inhibitor (SSRI). The distribution volumes of specific tracer binding (DV(3)') were calculated for 12 brain regions, and comparisons were made between: (1) healthy volunteers vs. untreated OCD patients, (2) healthy volunteers vs. treated OCD patients, and (3) OCD patients before and during treatment. When comparing the distribution volume for specific fronto-subcortical brain regions, significantly higher values were recorded in the caudate nuclei in OCD patients (DV(3)': 0.24+/-0.14) compared to the healthy control group (DV(3)': 0.15+/-0.13) (p<0.05, Wilcoxon matched-pairs test). This difference between groups was not present after treatment with SSRIs. There was no correlation between the severity of OCD symptoms and 5-HT(2A )receptor binding. An increase in 5-HT(2A) receptor binding is found in the caudate nuclei of untreated patients with OCD. The up-regulation in 5-HT(2A) receptors might be compensatory for a lack of serotonin in the feedback loop between the thalamus and orbito-frontal cortex, the caudate nuclei, and the globus pallidus.
Karen H Adams; Elsebeth S Hansen; Lars H Pinborg; Steen G Hasselbalch; Claus Svarer; Søren Holm; Tom G Bolwig; Gitte M Knudsen
Related Documents :
12607137 - Re-examination of a rey auditory verbal learning test/rey complex figure discriminant f...
18815387 - Cognitive impairment and structural brain damage in benign multiple sclerosis.
11827887 - Analysis of the cerebral cortex in holoprosencephaly with attention to the sylvian fiss...
16614037 - Diffusion tensor magnetic resonance imaging at 3.0 tesla shows subtle cerebral grey mat...
23637317 - Classification and diagnostic investigation in inflammatory myopathies: a study of 99 p...
25117727 - Three-dimensional analysis of acromial morphologic characteristics in patients with and...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2005-04-01
Journal Detail:
Title:  The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)     Volume:  8     ISSN:  1461-1457     ISO Abbreviation:  Int. J. Neuropsychopharmacol.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-06-24     Completed Date:  2006-07-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9815893     Medline TA:  Int J Neuropsychopharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  391-401     Citation Subset:  IM    
Neurobiology Research Unit (NRU), University Hospital of Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antidepressive Agents / pharmacology,  therapeutic use
Brain Mapping
Caudate Nucleus / drug effects,  metabolism*,  pathology
Fluorine Radioisotopes / pharmacokinetics
Ketanserin / analogs & derivatives,  pharmacokinetics
Magnetic Resonance Imaging / methods
Middle Aged
Obsessive-Compulsive Disorder / drug therapy*,  metabolism*,  pathology
Positron-Emission Tomography / methods
Protein Binding / drug effects,  physiology
Receptor, Serotonin, 5-HT2A / metabolism*
Reg. No./Substance:
0/Antidepressive Agents; 0/Fluorine Radioisotopes; 0/Receptor, Serotonin, 5-HT2A; 74050-98-9/Ketanserin; 76330-71-7/altanserin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Downregulation of calcineurin activity in cervical carcinoma.
Next Document:  Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring ty...